@article{TCR380,
author = {Ana Elisa Lohmann and Kamal S. Saini and Otto Metzger-Filho},
title = {Pertuzumab in metastatic breast cancer: unanswered questions},
journal = {Translational Cancer Research},
volume = {1},
number = {2},
year = {2012},
keywords = {},
abstract = {Recently, Baselga and colleagues published in New England Journal of Medicine the analyses of the Clinical Evaluation of Pertuzumab and Trastuzumab Study (CLEOPATRA) (1). CLEOPATRA is a phase III trial in 808 patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer receiving first line therapy with docetaxel and trastuzumab with placebo or pertuzumab until disease progression or unacceptable toxicity.},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/380}
}